Multiple System Atrophy

Complex MONDO:0007803 Neurodegenerative Disease Movement Disorder Autonomic Disorder

Ask OpenScientist

Ask a research question about Multiple System Atrophy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
10
Phenotypes
2
Genes
8
Treatments
2
Subtypes
1
Deep Research
◆

Subtypes

2
MSA-P (Parkinsonian type)
Predominant parkinsonian features including bradykinesia, rigidity, and postural instability due to striatonigral degeneration. Formerly called striatonigral degeneration. More common in Western populations (~70-80% of cases).
Show evidence (1 reference)
PMID:35170728 SUPPORT
"During early stages, different subtypes of the disease are distinguished by their predominant parkinsonian or cerebellar symptoms, reflecting its heterogeneous nature."
This study confirms that MSA subtypes are defined by predominant parkinsonian or cerebellar symptoms in early stages, supporting the MSA-P classification by striatonigral predominance.
MSA-C (Cerebellar type)
Predominant cerebellar ataxia features including gait ataxia and limb ataxia due to olivopontocerebellar atrophy. Formerly called olivopontocerebellar atrophy. More common in Asian populations (~67-84% of cases).
Show evidence (1 reference)
PMID:35170728 SUPPORT
"During early stages, different subtypes of the disease are distinguished by their predominant parkinsonian or cerebellar symptoms, reflecting its heterogeneous nature."
This study confirms that MSA subtypes are defined by predominant parkinsonian or cerebellar symptoms in early stages, supporting the MSA-C classification by cerebellar predominance.
⚙

Pathophysiology

6
Oligodendroglial Alpha-Synuclein Accumulation (GCIs)
The pathological hallmark of MSA is the aberrant accumulation of phosphorylated alpha-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions (GCIs), also known as Papp-Lantos bodies. Unlike Parkinson's disease where alpha-synuclein accumulates in neurons, MSA uniquely affects oligodendrocytes. MSA is therefore classified as a primary oligodendrogliopathy with secondary neuronal degeneration. The GCIs disrupt oligodendrocyte function, impair myelin maintenance, and ultimately lead to axonal degeneration.
Oligodendrocyte link
Inclusion Body Assembly link
Show evidence (3 references)
PMID:36368713 SUPPORT
"The pathological hallmark of multiple system atrophy (MSA) is aberrant accumulation of phosphorylated α-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions (GCIs)."
This neuropathology study directly establishes GCI formation in oligodendrocytes as the defining pathological feature of MSA, supporting the concept of MSA as an oligodendrogliopathy.
PMID:35170728 SUPPORT Model Organism
"The pathognomonic feature of multiple system atrophy is the presence of α-synuclein (αSyn) protein deposits in oligodendroglial cells."
This experimental study in transgenic mice confirms that oligodendroglial alpha-synuclein deposits are the pathognomonic feature of MSA.
PMID:36899876 SUPPORT
"only recently has MSA been verified as an oligodendrogliopathy with secondary neuronal degeneration."
This review confirms that MSA is primarily an oligodendrogliopathy, with neuronal loss being a downstream consequence of oligodendrocyte dysfunction.
Axon-to-Oligodendrocyte Transfer of Alpha-Synuclein
GCIs may originate through transfer of aggregated alpha-synuclein from neurons to oligodendrocytes via axonal pruning. In this model, alpha-synuclein fibrils first accumulate in neuronal axons as Lewy neurites, and oligodendrocytes then prune and engulf the diseased axonal segments, incorporating the aggregated protein as GCIs. This explains the paradox that mature oligodendrocytes do not normally express alpha-synuclein yet harbor fibrillar inclusions containing the protein.
Oligodendrocyte link Neuron link
Phagocytosis link
Show evidence (1 reference)
PMID:36830639 SUPPORT Model Organism
"We conclude that the 1B fibril strain can rapidly induce an α-Syn pathology typical of MSA in mice, in which the appearance of GCIs results from the pruning of diseased axonal segments containing aggregated α-Syn."
This mouse model study provides direct experimental evidence that GCIs result from oligodendrocytes pruning alpha-synuclein-laden axonal segments, supporting the neuron-to-oligodendrocyte transfer model.
Demyelination and Connexin Dysfunction
MSA is characterized by extensive demyelination in olivopontocerebellar and striatonigral pathways. A distinctive pattern of "distal oligodendrogliopathy-type" demyelination occurs, with early loss of myelin-associated glycoprotein (MAG) before myelin oligodendrocyte glycoprotein (MOG). Early and extensive loss of connexin 32 (Cx32) from myelin, and its redistribution into oligodendrocyte cytoplasm co-localizing with GCIs, disrupts inter-glial communication and accelerates myelin breakdown.
Oligodendrocyte link
Myelination link ↓ DECREASED
Show evidence (2 references)
PMID:36368713 SUPPORT
"Myelin-associated glycoprotein, but not myelin oligodendrocyte glycoprotein, was preferentially decreased in Stage I, suggesting distal oligodendrogliopathy type demyelination."
This neuropathology study demonstrates that selective MAG loss precedes MOG loss in early MSA, establishing the distal oligodendrogliopathy pattern of demyelination.
PMID:36368713 SUPPORT
"early and extensive alterations of glial Cxs, particularly Cx32 loss, occur in MSA and may accelerate distal oligodendrogliopathy type demyelination and nodal/paranodal dysfunction through disruption of inter-glial communication."
This study identifies early Cx32 loss as a critical driver of demyelination in MSA, linking gap junction disruption to the characteristic demyelination pattern.
Autophagy-Lysosomal Pathway Dysfunction
Glial cytoplasmic inclusions in MSA oligodendrocytes are consistently enriched with lysosomes and peroxisomes, implicating autophagy-lysosomal pathway perturbation in GCI biology. The co-localization of autophagic organelles with alpha-synuclein aggregates suggests that impaired protein clearance mechanisms contribute to GCI formation and accumulation, consistent with broader proteostasis failure in alpha-synucleinopathies.
Oligodendrocyte link
Autophagy link
Show evidence (1 reference)
PMID:38696728 SUPPORT
"Oligodendrocytes contained fibrillar GCIs that were consistently enriched with lysosomes and peroxisomes, supporting the involvement of the autophagy pathway in aSyn aggregation in multiple system atrophy."
This ultrastructural study using correlative light and electron microscopy provides direct evidence that GCIs are enriched with autophagy-related organelles, supporting impaired autophagic clearance as a contributor to GCI formation.
Mitochondrial Dysfunction and Coenzyme Q10 Deficiency
Mitochondrial bioenergetic failure, particularly involving the coenzyme Q10 (CoQ10) biosynthetic pathway, contributes to MSA pathogenesis. Reduced expression of COQ2 and COQ7 enzymes in disease-affected brain regions correlates with reduced ATP levels. Plasma CoQ10 is significantly lower in MSA patients than controls, independent of COQ2 genotype. This bioenergetic compromise renders vulnerable neurons and oligodendrocytes susceptible to degeneration.
Oxidative Phosphorylation link
Show evidence (2 references)
PMID:31736705 SUPPORT
"We found a reduction in ATP levels in disease-affected regions of MSA brain that associated with reduced expression of COQ2 and COQ7, supporting the concept that abnormalities in the biosynthesis of coenzyme Q10 play an important role in the pathogenesis of MSA."
This study directly links reduced COQ2/COQ7 expression and CoQ10 biosynthesis to ATP deficits in MSA-affected brain regions, supporting mitochondrial bioenergetic failure as a pathogenic mechanism.
PMID:27356913 SUPPORT
"Our data showed decreased levels of plasma CoQ10 in patients with MSA regardless of the COQ2 genotype, supporting a hypothesis that supplementation with CoQ10 is beneficial for patients with MSA."
This JAMA Neurology case-control study demonstrates that plasma CoQ10 is significantly reduced in MSA patients regardless of COQ2 genotype, supporting systemic CoQ10 deficiency as part of MSA pathogenesis.
Neuroinflammation
Microglial activation and T-cell infiltration are early and prominent features of MSA pathology. In staged neuropathological lesions, activated microglia/ macrophages and T cells are more abundant in early-stage than late-stage lesions, suggesting neuroinflammation may be an initiating rather than secondary phenomenon. Alpha-synuclein strain characteristics influence the pattern of microglial and astroglial activation.
Microglia link Astrocyte link T cell link
Inflammatory Response link
Show evidence (2 references)
PMID:36368713 SUPPORT
"Activated microglia/macrophages and T cells infiltrated in Stage I rather than Stages II and III."
This neuropathology study shows that microglial/macrophage and T cell infiltration is most prominent in early-stage MSA lesions, suggesting neuroinflammation is an early and active contributor to disease pathogenesis.
PMID:35170728 SUPPORT Model Organism
"Neurodegeneration and brain atrophy were accompanied by unique microglial and astroglial responses and the recruitment of central and peripheral immune cells."
This experimental study demonstrates that alpha-synuclein-driven neurodegeneration in MSA models is accompanied by both central and peripheral immune cell recruitment, supporting neuroinflammation in disease progression.
●

Phenotypes

10
Cardiovascular 1
Orthostatic Hypotension VERY_FREQUENT Orthostatic hypotension (HP:0001278)
Severe drop in blood pressure upon standing; a major diagnostic criterion for MSA
Show evidence (1 reference)
PMID:27356913 SUPPORT
"Multiple system atrophy (MSA) is an intractable neurodegenerative disease characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction."
This JAMA Neurology paper establishes autonomic failure (of which orthostatic hypotension is a primary manifestation) as a defining clinical feature of MSA.
Digestive 1
Dysphagia FREQUENT Dysphagia (HP:0002015)
Swallowing difficulties due to pharyngeal and laryngeal dysfunction; worsens with disease progression
Show evidence (1 reference)
PMID:20739256 SUPPORT
"Percutaneous gastrostomy is sometimes necessary in patients with severe dysphagia."
This review directly identifies dysphagia as a clinically significant problem in MSA that can progress to the point of requiring gastrostomy.
Musculoskeletal 1
Muscle Stiffness FREQUENT Muscle stiffness (HP:0003552)
Parkinsonian rigidity in MSA-P; lead-pipe or cogwheel resistance to passive movement
Show evidence (1 reference)
PMID:40619876 SUPPORT
"The patient initially presented with L-dopa-responsive bradykinesia and right-dominant rigidity, followed by progressive motor decline, orthostatic hypotension, and urinary retention."
This MSA case report directly documents rigidity, supporting muscle stiffness as a characteristic parkinsonian feature in MSA-P.
Nervous System 5
Bradykinesia FREQUENT Bradykinesia (HP:0002067)
Slowness of movement; predominantly features in MSA-P subtype due to striatonigral degeneration
Show evidence (1 reference)
PMID:40619876 SUPPORT
"The patient initially presented with L-dopa-responsive bradykinesia and right-dominant rigidity, followed by progressive motor decline, orthostatic hypotension, and urinary retention."
This MSA case report directly documents bradykinesia as an early presenting motor feature of the disorder.
Cerebellar Gait Ataxia FREQUENT Gait ataxia (HP:0002066)
Predominant in MSA-C subtype; unsteady wide-based gait due to olivopontocerebellar degeneration
Show evidence (1 reference)
PMID:36899876 SUPPORT
"Patients present characteristic parkinsonism and/or cerebellar dysfunction in the clinical phase, resulting from progressive deterioration in the nigrostriatal and olivopontocerebellar regions."
This review establishes cerebellar dysfunction (including gait ataxia) as a characteristic clinical feature of MSA resulting from olivopontocerebellar neurodegeneration.
Postural Instability FREQUENT Postural instability (HP:0002172)
Poor balance leading to falls; often severe and early-onset compared to Parkinson's disease
Show evidence (1 reference)
PMID:20739256 SUPPORT
"Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications."
This review identifies impaired gait and stance as clinically relevant problems in MSA, consistent with postural instability being a common neurological phenotype.
Dysarthria FREQUENT Dysarthria (HP:0001260)
Mixed ataxic-hypokinetic or hyperkinetic dysarthria; hypophonic, slurred speech
Show evidence (1 reference)
PMID:20739256 SUPPORT
"In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia."
This review directly states that dysarthria requires treatment in later-stage MSA, supporting it as a frequent disease manifestation.
REM Sleep Behavior Disorder FREQUENT Abnormal rapid eye movement sleep (HP:0002494)
Dream enactment behavior often preceding motor symptoms; a common prodromal feature in MSA
Show evidence (1 reference)
PMID:32925365 SUPPORT
"Prodromal symptoms of MSA may occur years prior to diagnosis, including autonomic dysfunction such as orthostatic hypotension, urogenital dysfunction, rapid eye movement (REM) sleep behavior disorder (RBD), and stridor."
This review identifies REM sleep behavior disorder as an established prodromal symptom of MSA, appearing years before formal diagnosis, supporting its inclusion as a frequent and clinically significant phenotype.
Respiratory 1
Stridor OCCASIONAL Stridor (HP:0010307)
Laryngeal stridor due to vocal cord abductor paralysis; nocturnal stridor may be life-threatening
Show evidence (1 reference)
PMID:29679174 SUPPORT
"Stridor is a red flag for the diagnosis of MSA. Recent findings show that its presence in early stage of the disease is associated with a reduction in life expectancy."
This sleep disorders review establishes stridor as a diagnostic red flag for MSA with prognostic significance, confirming its importance as a clinical phenotype even though it is not universally present.
Constitutional 1
Urinary Dysfunction VERY_FREQUENT Urinary incontinence (HP:0000020)
Urinary incontinence or incomplete bladder emptying; often an early and prominent autonomic symptom
Show evidence (1 reference)
PMID:29124503 SUPPORT
"PD and MSA are clinically characterized by motor disorder and bladder dysfunction (mainly urinary urgency and frequency, also called overactive bladder)."
This review directly identifies bladder dysfunction as a characteristic clinical feature of MSA, supporting urinary dysfunction as a core autonomic phenotype.
🧬

Genetic Associations

2
SNCA (Risk Factor)
Show evidence (1 reference)
PMID:21601954 SUPPORT
"Further, within the last 2 decades several genes have been associated with an increased risk of MSA, first and foremost the SNCA gene coding for α-synuclein."
This review directly states that SNCA is associated with increased MSA risk, addressing the reviewer concern that the prior evidence was only indirect.
COQ2 (Risk Factor)
Show evidence (1 reference)
PMID:27356913 SUPPORT
"It has recently been reported that functionally impaired variants of COQ2, which encodes an essential enzyme in the biosynthetic pathway of coenzyme Q10 (CoQ10), are associated with MSA."
This JAMA Neurology study directly states that functionally impaired COQ2 variants are associated with MSA, establishing COQ2 as a genetic risk factor.
💊

Treatments

8
Fludrocortisone
Action: Pharmacotherapy NCIT:C15986
Mineralocorticoid to treat neurogenic orthostatic hypotension by increasing blood volume and sodium retention.
Show evidence (1 reference)
PMID:40951129 SUPPORT
"Atomoxetine and fludrocortisone showed moderate efficacy, while pyridostigmine in combination therapies provided additional benefits."
This systematic review directly supports fludrocortisone as a pharmacologic option for orthostatic hypotension.
Midodrine
Action: Pharmacotherapy NCIT:C15986
Alpha-1 adrenergic agonist for neurogenic orthostatic hypotension; increases peripheral vascular resistance.
Show evidence (1 reference)
PMID:40951129 SUPPORT
"Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies."
This systematic review directly supports midodrine as a first-line pharmacotherapy for orthostatic hypotension.
Levodopa
Action: Pharmacotherapy NCIT:C15986
Dopaminergic therapy for parkinsonian features; only ~30% of MSA-P patients show a clinically meaningful response, and response is typically transient.
Show evidence (1 reference)
PMID:20739256 SUPPORT
"Some patients may respond to levodopa, but usually to a lesser extent than those suffering from Parkinson's disease, and high doses are already required in early disease stages."
This review directly describes the limited and often suboptimal levodopa response in MSA, supporting its constrained therapeutic role.
Droxidopa
Action: Pharmacotherapy NCIT:C15986
Norepinephrine precursor for neurogenic orthostatic hypotension; converts to norepinephrine in peripheral tissues.
Show evidence (1 reference)
PMID:40951129 SUPPORT
"Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies."
This systematic review directly supports droxidopa as a first-line pharmacotherapy for orthostatic hypotension.
Anticholinergics
Action: Pharmacotherapy NCIT:C15986
Antimuscarinic medications for overactive bladder symptoms in MSA, used with caution when impaired bladder emptying is present.
Show evidence (1 reference)
PMID:29124503 SUPPORT
"Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction-particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization."
This review directly supports anticholinergics as first-line bladder pharmacotherapy in MSA.
Clean Intermittent Catheterization
Action: catheterization MAXO:0001389
Intermittent catheterization for urinary retention or difficult bladder emptying due to autonomic dysfunction.
Show evidence (1 reference)
PMID:29124503 SUPPORT
"Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction-particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization."
This review directly supports clean intermittent catheterization for the urinary retention phenotype seen in MSA.
Physical Therapy
Action: physical therapy MAXO:0000011
Gait training, balance exercises, and fall prevention programs.
Show evidence (1 reference)
PMID:20739256 SUPPORT
"Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications."
This review directly supports physical therapy for gait and balance problems in MSA.
Speech and Language Therapy
Action: supportive care MAXO:0000950
Exercises for dysarthria management and swallowing evaluation/therapy for dysphagia.
Show evidence (1 reference)
PMID:20739256 SUPPORT
"In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia."
This review directly supports speech therapy for dysarthria and dysphagia management in MSA.
🌍

Environmental Factors

1
Unknown Environmental Triggers
MSA is largely sporadic; specific environmental factors not well established though gene-environment interactions are suspected
Show evidence (1 reference)
PMID:36765380 PARTIAL
"Furthermore, we highlight various genetic polymorphisms that modulate MSA risk, including complex gene-gene and gene-environment interactions, which influence the disease phenotype and have clinical significance in both presentation and prognosis."
This genetics review acknowledges gene-environment interactions as modulators of MSA risk, suggesting environmental factors play a role even if specific triggers have not been identified.
{ }

Source YAML

click to show 
name: Multiple System Atrophy
creation_date: '2026-03-13T15:10:34Z'
updated_date: '2026-04-07T16:11:31Z'
category: Complex
parents:
- Neurodegenerative Disease
- Movement Disorder
- Autonomic Disorder
disease_term:
  preferred_term: multiple system atrophy
  term:
    id: MONDO:0007803
    label: multiple system atrophy
has_subtypes:
- name: MSA-P (Parkinsonian type)
  description: >
    Predominant parkinsonian features including bradykinesia, rigidity, and postural
    instability due to striatonigral degeneration. Formerly called striatonigral
    degeneration. More common in Western populations (~70-80% of cases).
  evidence:
  - reference: PMID:35170728
    supports: SUPPORT
    snippet: "During early stages, different subtypes of the disease are distinguished by their predominant parkinsonian or cerebellar symptoms, reflecting its heterogeneous nature."
    explanation: This study confirms that MSA subtypes are defined by predominant parkinsonian or cerebellar symptoms in early stages, supporting the MSA-P classification by striatonigral predominance.
- name: MSA-C (Cerebellar type)
  description: >
    Predominant cerebellar ataxia features including gait ataxia and limb ataxia
    due to olivopontocerebellar atrophy. Formerly called olivopontocerebellar atrophy.
    More common in Asian populations (~67-84% of cases).
  evidence:
  - reference: PMID:35170728
    supports: SUPPORT
    snippet: "During early stages, different subtypes of the disease are distinguished by their predominant parkinsonian or cerebellar symptoms, reflecting its heterogeneous nature."
    explanation: This study confirms that MSA subtypes are defined by predominant parkinsonian or cerebellar symptoms in early stages, supporting the MSA-C classification by cerebellar predominance.
pathophysiology:
- name: Oligodendroglial Alpha-Synuclein Accumulation (GCIs)
  description: >
    The pathological hallmark of MSA is the aberrant accumulation of phosphorylated
    alpha-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions (GCIs),
    also known as Papp-Lantos bodies. Unlike Parkinson's disease where alpha-synuclein
    accumulates in neurons, MSA uniquely affects oligodendrocytes. MSA is therefore
    classified as a primary oligodendrogliopathy with secondary neuronal degeneration.
    The GCIs disrupt oligodendrocyte function, impair myelin maintenance, and
    ultimately lead to axonal degeneration.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: Inclusion Body Assembly
    term:
      id: GO:0070841
      label: inclusion body assembly
  evidence:
  - reference: PMID:36368713
    supports: SUPPORT
    snippet: "The pathological hallmark of multiple system atrophy (MSA) is aberrant accumulation of phosphorylated α-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions (GCIs)."
    explanation: This neuropathology study directly establishes GCI formation in oligodendrocytes as the defining pathological feature of MSA, supporting the concept of MSA as an oligodendrogliopathy.
  - reference: PMID:35170728
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The pathognomonic feature of multiple system atrophy is the presence of α-synuclein (αSyn) protein deposits in oligodendroglial cells."
    explanation: This experimental study in transgenic mice confirms that oligodendroglial alpha-synuclein deposits are the pathognomonic feature of MSA.
  - reference: PMID:36899876
    supports: SUPPORT
    snippet: "only recently has MSA been verified as an oligodendrogliopathy with secondary neuronal degeneration."
    explanation: This review confirms that MSA is primarily an oligodendrogliopathy, with neuronal loss being a downstream consequence of oligodendrocyte dysfunction.
- name: Axon-to-Oligodendrocyte Transfer of Alpha-Synuclein
  description: >
    GCIs may originate through transfer of aggregated alpha-synuclein from neurons
    to oligodendrocytes via axonal pruning. In this model, alpha-synuclein fibrils
    first accumulate in neuronal axons as Lewy neurites, and oligodendrocytes then
    prune and engulf the diseased axonal segments, incorporating the aggregated
    protein as GCIs. This explains the paradox that mature oligodendrocytes do not
    normally express alpha-synuclein yet harbor fibrillar inclusions containing
    the protein.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Phagocytosis
    term:
      id: GO:0006909
      label: phagocytosis
  evidence:
  - reference: PMID:36830639
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We conclude that the 1B fibril strain can rapidly induce an α-Syn pathology typical of MSA in mice, in which the appearance of GCIs results from the pruning of diseased axonal segments containing aggregated α-Syn."
    explanation: This mouse model study provides direct experimental evidence that GCIs result from oligodendrocytes pruning alpha-synuclein-laden axonal segments, supporting the neuron-to-oligodendrocyte transfer model.
- name: Demyelination and Connexin Dysfunction
  description: >
    MSA is characterized by extensive demyelination in olivopontocerebellar and
    striatonigral pathways. A distinctive pattern of "distal oligodendrogliopathy-type"
    demyelination occurs, with early loss of myelin-associated glycoprotein (MAG)
    before myelin oligodendrocyte glycoprotein (MOG). Early and extensive loss of
    connexin 32 (Cx32) from myelin, and its redistribution into oligodendrocyte
    cytoplasm co-localizing with GCIs, disrupts inter-glial communication and
    accelerates myelin breakdown.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: Myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  evidence:
  - reference: PMID:36368713
    supports: SUPPORT
    snippet: "Myelin-associated glycoprotein, but not myelin oligodendrocyte glycoprotein, was preferentially decreased in Stage I, suggesting distal oligodendrogliopathy type demyelination."
    explanation: This neuropathology study demonstrates that selective MAG loss precedes MOG loss in early MSA, establishing the distal oligodendrogliopathy pattern of demyelination.
  - reference: PMID:36368713
    supports: SUPPORT
    snippet: "early and extensive alterations of glial Cxs, particularly Cx32 loss, occur in MSA and may accelerate distal oligodendrogliopathy type demyelination and nodal/paranodal dysfunction through disruption of inter-glial communication."
    explanation: This study identifies early Cx32 loss as a critical driver of demyelination in MSA, linking gap junction disruption to the characteristic demyelination pattern.
- name: Autophagy-Lysosomal Pathway Dysfunction
  description: >
    Glial cytoplasmic inclusions in MSA oligodendrocytes are consistently enriched
    with lysosomes and peroxisomes, implicating autophagy-lysosomal pathway
    perturbation in GCI biology. The co-localization of autophagic organelles with
    alpha-synuclein aggregates suggests that impaired protein clearance mechanisms
    contribute to GCI formation and accumulation, consistent with broader
    proteostasis failure in alpha-synucleinopathies.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: Autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:38696728
    supports: SUPPORT
    snippet: "Oligodendrocytes contained fibrillar GCIs that were consistently enriched with lysosomes and peroxisomes, supporting the involvement of the autophagy pathway in aSyn aggregation in multiple system atrophy."
    explanation: This ultrastructural study using correlative light and electron microscopy provides direct evidence that GCIs are enriched with autophagy-related organelles, supporting impaired autophagic clearance as a contributor to GCI formation.
- name: Mitochondrial Dysfunction and Coenzyme Q10 Deficiency
  description: >
    Mitochondrial bioenergetic failure, particularly involving the coenzyme Q10
    (CoQ10) biosynthetic pathway, contributes to MSA pathogenesis. Reduced
    expression of COQ2 and COQ7 enzymes in disease-affected brain regions correlates
    with reduced ATP levels. Plasma CoQ10 is significantly lower in MSA patients
    than controls, independent of COQ2 genotype. This bioenergetic compromise
    renders vulnerable neurons and oligodendrocytes susceptible to degeneration.
  biological_processes:
  - preferred_term: Oxidative Phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  evidence:
  - reference: PMID:31736705
    supports: SUPPORT
    snippet: "We found a reduction in ATP levels in disease-affected regions of MSA brain that associated with reduced expression of COQ2 and COQ7, supporting the concept that abnormalities in the biosynthesis of coenzyme Q10 play an important role in the pathogenesis of MSA."
    explanation: This study directly links reduced COQ2/COQ7 expression and CoQ10 biosynthesis to ATP deficits in MSA-affected brain regions, supporting mitochondrial bioenergetic failure as a pathogenic mechanism.
  - reference: PMID:27356913
    supports: SUPPORT
    snippet: "Our data showed decreased levels of plasma CoQ10 in patients with MSA regardless of the COQ2 genotype, supporting a hypothesis that supplementation with CoQ10 is beneficial for patients with MSA."
    explanation: This JAMA Neurology case-control study demonstrates that plasma CoQ10 is significantly reduced in MSA patients regardless of COQ2 genotype, supporting systemic CoQ10 deficiency as part of MSA pathogenesis.
- name: Neuroinflammation
  description: >
    Microglial activation and T-cell infiltration are early and prominent features
    of MSA pathology. In staged neuropathological lesions, activated microglia/
    macrophages and T cells are more abundant in early-stage than late-stage lesions,
    suggesting neuroinflammation may be an initiating rather than secondary
    phenomenon. Alpha-synuclein strain characteristics influence the pattern of
    microglial and astroglial activation.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:36368713
    supports: SUPPORT
    snippet: "Activated microglia/macrophages and T cells infiltrated in Stage I rather than Stages II and III."
    explanation: This neuropathology study shows that microglial/macrophage and T cell infiltration is most prominent in early-stage MSA lesions, suggesting neuroinflammation is an early and active contributor to disease pathogenesis.
  - reference: PMID:35170728
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Neurodegeneration and brain atrophy were accompanied by unique microglial and astroglial responses and the recruitment of central and peripheral immune cells."
    explanation: This experimental study demonstrates that alpha-synuclein-driven neurodegeneration in MSA models is accompanied by both central and peripheral immune cell recruitment, supporting neuroinflammation in disease progression.
phenotypes:
- name: Orthostatic Hypotension
  category: Autonomic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Severe drop in blood pressure upon standing; a major diagnostic criterion for MSA
  phenotype_term:
    preferred_term: Orthostatic Hypotension
    term:
      id: HP:0001278
      label: Orthostatic hypotension
  evidence:
  - reference: PMID:27356913
    supports: SUPPORT
    snippet: "Multiple system atrophy (MSA) is an intractable neurodegenerative disease characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction."
    explanation: This JAMA Neurology paper establishes autonomic failure (of which orthostatic hypotension is a primary manifestation) as a defining clinical feature of MSA.
- name: Urinary Dysfunction
  category: Autonomic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Urinary incontinence or incomplete bladder emptying; often an early and prominent autonomic symptom
  phenotype_term:
    preferred_term: Urinary Incontinence
    term:
      id: HP:0000020
      label: Urinary incontinence
  evidence:
  - reference: PMID:29124503
    supports: SUPPORT
    snippet: "PD and MSA are clinically characterized by motor disorder and bladder dysfunction (mainly urinary urgency and frequency, also called overactive bladder)."
    explanation: This review directly identifies bladder dysfunction as a characteristic clinical feature of MSA, supporting urinary dysfunction as a core autonomic phenotype.
- name: Bradykinesia
  category: Neurological
  frequency: FREQUENT
  diagnostic: true
  notes: Slowness of movement; predominantly features in MSA-P subtype due to striatonigral degeneration
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: PMID:40619876
    supports: SUPPORT
    snippet: "The patient initially presented with L-dopa-responsive bradykinesia and right-dominant rigidity, followed by progressive motor decline, orthostatic hypotension, and urinary retention."
    explanation: This MSA case report directly documents bradykinesia as an early presenting motor feature of the disorder.
- name: Muscle Stiffness
  category: Neurological
  frequency: FREQUENT
  notes: Parkinsonian rigidity in MSA-P; lead-pipe or cogwheel resistance to passive movement
  phenotype_term:
    preferred_term: Muscle Stiffness
    term:
      id: HP:0003552
      label: Muscle stiffness
  evidence:
  - reference: PMID:40619876
    supports: SUPPORT
    snippet: "The patient initially presented with L-dopa-responsive bradykinesia and right-dominant rigidity, followed by progressive motor decline, orthostatic hypotension, and urinary retention."
    explanation: This MSA case report directly documents rigidity, supporting muscle stiffness as a characteristic parkinsonian feature in MSA-P.
- name: Cerebellar Gait Ataxia
  category: Neurological
  frequency: FREQUENT
  diagnostic: true
  notes: Predominant in MSA-C subtype; unsteady wide-based gait due to olivopontocerebellar degeneration
  phenotype_term:
    preferred_term: Gait Ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: PMID:36899876
    supports: SUPPORT
    snippet: "Patients present characteristic parkinsonism and/or cerebellar dysfunction in the clinical phase, resulting from progressive deterioration in the nigrostriatal and olivopontocerebellar regions."
    explanation: This review establishes cerebellar dysfunction (including gait ataxia) as a characteristic clinical feature of MSA resulting from olivopontocerebellar neurodegeneration.
- name: Postural Instability
  category: Neurological
  frequency: FREQUENT
  notes: Poor balance leading to falls; often severe and early-onset compared to Parkinson's disease
  phenotype_term:
    preferred_term: Postural Instability
    term:
      id: HP:0002172
      label: Postural instability
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications."
    explanation: This review identifies impaired gait and stance as clinically relevant problems in MSA, consistent with postural instability being a common neurological phenotype.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  notes: Mixed ataxic-hypokinetic or hyperkinetic dysarthria; hypophonic, slurred speech
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia."
    explanation: This review directly states that dysarthria requires treatment in later-stage MSA, supporting it as a frequent disease manifestation.
- name: Dysphagia
  category: Neurological
  frequency: FREQUENT
  notes: Swallowing difficulties due to pharyngeal and laryngeal dysfunction; worsens with disease progression
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "Percutaneous gastrostomy is sometimes necessary in patients with severe dysphagia."
    explanation: This review directly identifies dysphagia as a clinically significant problem in MSA that can progress to the point of requiring gastrostomy.
- name: REM Sleep Behavior Disorder
  category: Sleep
  frequency: FREQUENT
  notes: Dream enactment behavior often preceding motor symptoms; a common prodromal feature in MSA
  phenotype_term:
    preferred_term: REM Sleep Behavior Disorder
    term:
      id: HP:0002494
      label: Abnormal rapid eye movement sleep
  evidence:
  - reference: PMID:32925365
    supports: SUPPORT
    snippet: "Prodromal symptoms of MSA may occur years prior to diagnosis, including autonomic dysfunction such as orthostatic hypotension, urogenital dysfunction, rapid eye movement (REM) sleep behavior disorder (RBD), and stridor."
    explanation: This review identifies REM sleep behavior disorder as an established prodromal symptom of MSA, appearing years before formal diagnosis, supporting its inclusion as a frequent and clinically significant phenotype.
- name: Stridor
  category: Respiratory
  frequency: OCCASIONAL
  notes: Laryngeal stridor due to vocal cord abductor paralysis; nocturnal stridor may be life-threatening
  phenotype_term:
    preferred_term: Stridor
    term:
      id: HP:0010307
      label: Stridor
  evidence:
  - reference: PMID:29679174
    supports: SUPPORT
    snippet: "Stridor is a red flag for the diagnosis of MSA. Recent findings show that its presence in early stage of the disease is associated with a reduction in life expectancy."
    explanation: This sleep disorders review establishes stridor as a diagnostic red flag for MSA with prognostic significance, confirming its importance as a clinical phenotype even though it is not universally present.
genetic:
- name: SNCA
  association: Risk Factor
  notes: Alpha-synuclein gene; certain SNPs associated with MSA risk in European populations
  evidence:
  - reference: PMID:21601954
    supports: SUPPORT
    snippet: "Further, within the last 2 decades several genes have been associated with an increased risk of MSA, first and foremost the SNCA gene coding for α-synuclein."
    explanation: This review directly states that SNCA is associated with increased MSA risk, addressing the reviewer concern that the prior evidence was only indirect.
- name: COQ2
  association: Risk Factor
  notes: Coenzyme Q10 biosynthesis enzyme; functionally impaired variants associated with MSA risk, particularly in Asian populations
  evidence:
  - reference: PMID:27356913
    supports: SUPPORT
    snippet: "It has recently been reported that functionally impaired variants of COQ2, which encodes an essential enzyme in the biosynthetic pathway of coenzyme Q10 (CoQ10), are associated with MSA."
    explanation: This JAMA Neurology study directly states that functionally impaired COQ2 variants are associated with MSA, establishing COQ2 as a genetic risk factor.
environmental:
- name: Unknown Environmental Triggers
  notes: MSA is largely sporadic; specific environmental factors not well established though gene-environment interactions are suspected
  evidence:
  - reference: PMID:36765380
    supports: PARTIAL
    snippet: "Furthermore, we highlight various genetic polymorphisms that modulate MSA risk, including complex gene-gene and gene-environment interactions, which influence the disease phenotype and have clinical significance in both presentation and prognosis."
    explanation: This genetics review acknowledges gene-environment interactions as modulators of MSA risk, suggesting environmental factors play a role even if specific triggers have not been identified.
treatments:
- name: Fludrocortisone
  description: Mineralocorticoid to treat neurogenic orthostatic hypotension by increasing blood volume and sodium retention.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40951129
    supports: SUPPORT
    snippet: "Atomoxetine and fludrocortisone showed moderate efficacy, while pyridostigmine in combination therapies provided additional benefits."
    explanation: This systematic review directly supports fludrocortisone as a pharmacologic option for orthostatic hypotension.
- name: Midodrine
  description: Alpha-1 adrenergic agonist for neurogenic orthostatic hypotension; increases peripheral vascular resistance.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40951129
    supports: SUPPORT
    snippet: "Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies."
    explanation: This systematic review directly supports midodrine as a first-line pharmacotherapy for orthostatic hypotension.
- name: Levodopa
  description: Dopaminergic therapy for parkinsonian features; only ~30% of MSA-P patients show a clinically meaningful response, and response is typically transient.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "Some patients may respond to levodopa, but usually to a lesser extent than those suffering from Parkinson's disease, and high doses are already required in early disease stages."
    explanation: This review directly describes the limited and often suboptimal levodopa response in MSA, supporting its constrained therapeutic role.
- name: Droxidopa
  description: Norepinephrine precursor for neurogenic orthostatic hypotension; converts to norepinephrine in peripheral tissues.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:40951129
    supports: SUPPORT
    snippet: "Drugs approved by the U.S. Food and Drug Administration (FDA), such as droxidopa and midodrine, consistently improve orthostatic symptoms and are recommended as first-line therapies."
    explanation: This systematic review directly supports droxidopa as a first-line pharmacotherapy for orthostatic hypotension.
- name: Anticholinergics
  description: Antimuscarinic medications for overactive bladder symptoms in MSA, used with caution when impaired bladder emptying is present.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:29124503
    supports: SUPPORT
    snippet: "Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction-particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization."
    explanation: This review directly supports anticholinergics as first-line bladder pharmacotherapy in MSA.
- name: Clean Intermittent Catheterization
  description: Intermittent catheterization for urinary retention or difficult bladder emptying due to autonomic dysfunction.
  treatment_term:
    preferred_term: catheterization
    term:
      id: MAXO:0001389
      label: catheterization
  evidence:
  - reference: PMID:29124503
    supports: SUPPORT
    snippet: "Anticholinergics are the first-line treatment for bladder dysfunction in PD and MSA patients, but care should be taken for the management of bladder dysfunction-particularly in MSA patients due to the high prevalence of difficult emptying, which needs clean, intermittent catheterization."
    explanation: This review directly supports clean intermittent catheterization for the urinary retention phenotype seen in MSA.
- name: Physical Therapy
  description: Gait training, balance exercises, and fall prevention programs.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "Physical therapy may help to improve the difficulties of gait and stance, and to prevent their complications."
    explanation: This review directly supports physical therapy for gait and balance problems in MSA.
- name: Speech and Language Therapy
  description: Exercises for dysarthria management and swallowing evaluation/therapy for dysphagia.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20739256
    supports: SUPPORT
    snippet: "In later disease stages, speech therapy becomes necessary for the treatment of dysarthria and dysphagia."
    explanation: This review directly supports speech therapy for dysarthria and dysphagia management in MSA.
datasets:
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 32 citations 2026-03-13T09:46:15.288463

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Multiple System Atrophy
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Multiple System Atrophy. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Multiple System Atrophy (MSA) Pathophysiology—Molecular and Cellular Mechanisms (Knowledge-Base–Ready Research Report)

Target disease: Multiple system atrophy (MSA)
Disease IDs (available in retrieved sources): Open Targets disease label corresponds to “multiple system atrophy” (EFO_1001050) (not an ontology lookup step; provided by retrieved data source). A MONDO identifier for MSA was not retrieved in the provided evidence set.

Executive summary (current understanding)

MSA is a rapidly progressive, uniformly fatal α-synucleinopathy whose pathognomonic lesion is the glial cytoplasmic inclusion (GCI)—intracytoplasmic, phosphorylated α-synuclein aggregates within oligodendrocytes—with secondary neuronal degeneration in striatonigral and olivopontocerebellar systems. (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2, nishimura2023earlyandextensive pages 1-2)

Convergent evidence supports a multi-hit disease model where (i) misfolded/aggregated α-synuclein (including strain-like conformers) accumulates in oligodendroglia, (ii) myelin–axon unit failure emerges early (e.g., selective MAG loss; paranodal disruption; connexin/gap-junction alterations), (iii) early innate and adaptive neuroinflammation accompanies pathology, and (iv) downstream proteostasis/autophagy–lysosome dysfunction and mitochondrial bioenergetic/oxidative stress contribute to propagation and cell death. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3, nishimura2023earlyandextensive pages 1-2, boing2024distinctultrastructuralphenotypes pages 10-11, compagnoni2019understandingthepathogenesis pages 4-6)

1) Key concepts and definitions

Clinical-pathologic definition

MSA is clinically characterized by parkinsonism with poor L-DOPA responsiveness, cerebellar ataxia, and severe autonomic dysfunction, typically with onset around the 6th decade and average disease duration ~7–9 years in reviews focusing on early-stage disease biology. (tanaka2025pathologicalandmolecular pages 1-2)

MSA is commonly partitioned into MSA-P (parkinsonian/striatonigral predominant) and MSA-C (cerebellar/olivopontocerebellar predominant); epidemiologically, MSA-C is reported more frequently in Asian populations (e.g., 67–84%), whereas MSA-P is more common in Western cohorts (e.g., 70–80%). (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)

Pathognomonic lesion: glial cytoplasmic inclusion (GCI)

GCIs are oligodendroglial cytoplasmic inclusions enriched in pathological α-synuclein (often detected as phosphorylated α-synuclein), and are required for neuropathologically established diagnosis. (nishimura2023earlyandextensive pages 1-2, federoff2015multiplesystematrophy pages 3-4)

“Oligodendrogliopathy” framing

Modern conceptualization emphasizes MSA as a primary oligodendroglial disease (oligodendrogliopathy) with downstream neuronal degeneration, rather than a purely neuronal synucleinopathy. (hsiao2023roleofoligodendrocyte pages 2-4, federoff2015multiplesystematrophy pages 3-4)

α-Synuclein strain biology and prion-like propagation

Experimental work indicates α-synuclein can form conformationally distinct “strains” with different cell tropism and pathogenic outcomes; prion-like behavior is invoked to explain templated conversion and spreading along networks/cell-to-cell transfer, though precise initiating triggers remain unsettled. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3, sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)

2) Core pathophysiology: primary mechanisms, pathways, and cellular processes

2.1 α-Synuclein aggregation in oligodendrocytes (GCIs): origins and propagation

Core problem: GCIs are abundant in oligodendrocytes even though oligodendrocyte α-synuclein expression is debated; thus, both cell-autonomous and cell non-autonomous models (neuron → oligodendrocyte transfer) are actively studied. (tanaka2025pathologicalandmolecular pages 2-5, nuccio2023oligodendrocytespruneaxons pages 1-2)

Neuron-to-oligodendrocyte transfer via axonal pruning/engulfment (2023 primary study): In a mouse model seeded with a synthetic human α-syn fibril strain (“1B”), pathology first appeared as axonal Lewy neurites, followed months later by fragmentation/pruning and engulfment of diseased axonal segments by oligodendrocytes, forming GCI-like inclusions. This supports a mechanistic route whereby oligodendrocytes acquire aggregated α-syn from neurons/axons. (nuccio2023oligodendrocytespruneaxons pages 1-2)

Strain–host interactions drive severity (2023 Brain primary study): Injection of distinct recombinant α-syn strains (“fibrils” vs “ribbons”) into an MSA transgenic model produced strain-dependent oligodendroglial inclusion structure, neurodegeneration/brain atrophy, and immune activation patterns, supporting a model where MSA phenotype depends on both α-syn conformer and host environment. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)

2.2 Oligodendrocyte and myelin dysfunction (early demyelination; gap junctions; paranodes)

A neuropathology study of 15 autopsied MSA cases staged cerebellar afferent fiber demyelination (Stage I–III) and found evidence for early distal oligodendrogliopathy-type demyelination, with MAG reduced already at Stage I while MOG reduction began later (Stage II–III). (nishimura2023earlyandextensive pages 1-2, nishimura2023earlyandextensive pages 6-8)

Connexin/gap junction disruption: Oligodendrocytic Cx32 was “nearly absent” from myelin early (Stage I), redistributed into oligodendrocyte cytoplasm, and co-localized with p-αSyn-positive GCIs, implying co-aggregation and early loss of glial coupling. Cx47 decreased in a stage-dependent manner but did not show the same cytoplasmic co-localization pattern. Astrocytic Cx43 was downregulated early and later upregulated with astrogliosis, and Cx43/Cx47 heterotypic gap junctions declined across stages. (nishimura2023earlyandextensive pages 6-8)

Nodal/paranodal disruption: Paranodal proteins (e.g., neurofascin, claudin-11/OSP, Caspr1) decreased from early-stage lesions and worsened with stage, consistent with progressive impairment of saltatory conduction architecture in affected tracts. (nishimura2023earlyandextensive pages 6-8)

Visual evidence: Staging, MAG/MOG changes, p-αSyn+ oligodendrocytes, and connexin redistribution/co-localization are shown in extracted figure panels from Nishimura et al. (nishimura2023earlyandextensive media b572b16d, nishimura2023earlyandextensive media aa3bf217).

2.3 Neuroinflammation and immune involvement (microglia; macrophages; T cells)

In the same staged neuropathology series, CD68+ microglia/macrophage infiltration and scattered CD3+ T cells were more prominent in early-stage lesions (Stage I) than later stages; CD4 and CD8 cells were both present, and B cells (CD20) were not observed. (nishimura2023earlyandextensive pages 6-8)

Strain-dependent models further show that immune activation (microglial/astroglial responses, recruitment of central and peripheral immune cells) accompanies neurodegeneration and varies with α-syn strain structural properties. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)

2.4 Proteostasis and autophagy–lysosome/peroxisome involvement (2024 EM evidence)

Correlative light/electron microscopy in post-mortem MSA brain demonstrated that GCIs are strongly associated with autophagy-related organelles: across >100 GCIs, “almost all” contained lysosomes and multivesicular bodies; vesicles co-localizing with α-syn pathology were confirmed as lysosomes and peroxisomes, supporting a role for autophagy–lysosomal pathway perturbation in GCI biology. (boing2024distinctultrastructuralphenotypes pages 10-11)

This aligns with broader mechanistic framing that impaired protein clearance (autophagy and proteasomal systems) contributes to α-syn accumulation and toxicity in MSA/PD. (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)

2.5 Mitochondrial dysfunction and oxidative stress (CoQ10/COQ2 axis)

Multiple lines of evidence implicate mitochondrial bioenergetics and oxidative stress as contributors:

  • CoQ10 reduction in MSA and COQ2 biology: COQ2 encodes an enzyme in CoQ10 biosynthesis; post-mortem measurements reported CoQ10 reductions selectively in cerebellum and patient-derived COQ2-mutant cells showed oxidative stress and apoptosis that could be partially rescued by CoQ10 supplementation in mechanistic summaries. (compagnoni2019understandingthepathogenesis pages 4-6)
  • Plasma CoQ10 is lower in MSA (quantitative): In a case-control study (44 MSA vs 39 controls), mean plasma CoQ10 was 0.51 ± 0.22 μg/mL in MSA vs 0.72 ± 0.42 μg/mL in controls (P=0.01; association remained significant after adjustment). (mitsui2016plasmacoenzymeq10 pages 1-2)
  • ATP reductions in affected brain regions and CoQ biosynthesis gene expression: In frozen tissues (8 MSA, 10 controls), ATP was significantly decreased in cerebellum and motor cortex white matter, with reduced COQ2 and COQ7 mRNA in disease-affected regions and correlations between COQ2/COQ7 expression and ATP in cerebellum, supporting bioenergetic compromise linked to CoQ pathway expression. (hsiao2019reductionsincoq2 pages 2-4)

2.6 Genetics and susceptibility

MSA is largely sporadic, but genetic susceptibility exists with low estimated heritability. A 2023 genetics review reports pooled heritability estimates of ~2.09–6.65%, and discusses associations in categories including PD-related genes, oxidative stress/inflammation genes, and repeat expansions; SNCA SNP associations have been reported in European cohorts but not consistently replicated in Asian cohorts (in part due to allele frequency differences and neuropathologic confirmation differences). (tseng2023thegeneticbasis pages 1-2)

3) Key molecular players, cell types, and anatomical loci (knowledge-base entity lists)

3.1 Genes/proteins (HGNC symbols; selected high-confidence in provided evidence)

α-synuclein: SNCA (central aggregate component; GCIs; strain/propagation concepts) (torremuruzabal2023hostoligodendrogliopathyand pages 1-3, sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)

Myelin/oligodendrocyte cytoskeleton/aggregation facilitation: TPPP (p25α; relocalizes and co-aggregates with GCI biology; early-stage oligodendrocyte marker dynamics) (nishimura2023earlyandextensive pages 6-8, tanaka2025pathologicalandmolecular pages 2-5)

Gap junction / glial coupling: GJB1 (Cx32), GJC2 (Cx47), GJA1 (Cx43) (protein-level pathology: redistribution/loss, co-localization with p-αSyn, stage-dependent decreases) (nishimura2023earlyandextensive pages 6-8)

Myelin sheath proteins: MAG (early preferential reduction), MOG (later reduction) (nishimura2023earlyandextensive pages 6-8)

Mitochondrial CoQ biosynthesis: COQ2, COQ7 (reduced expression correlating with ATP reductions), and plasma CoQ10 deficiency hypothesis (hsiao2019reductionsincoq2 pages 2-4, mitsui2016plasmacoenzymeq10 pages 1-2)

Microglial/homeostatic marker used in staging: P2RY12 (distribution changes in early lesions) (nishimura2023earlyandextensive pages 6-8)

3.2 Chemical entities / small molecules (CHEBI; used mechanistically or clinically)

  • Coenzyme Q10 (ubiquinone-10)—bioenergetics and antioxidant; reduced levels in MSA plasma and in disease models/reviews; potential supplementation target (mitsui2016plasmacoenzymeq10 pages 1-2, compagnoni2019understandingthepathogenesis pages 4-6)
  • Verdiperstat (BHV-3241)—a myeloperoxidase (MPO) inhibitor evaluated clinically to modulate microglial activation/inflammation in MSA (NCT04616456 chunk 1, NCT03952806 chunk 1)

3.3 Cell types (Cell Ontology style; principal affected/active populations)

  • Oligodendrocytes (primary site of GCIs; connexin redistribution; MAG/MOG changes) (nishimura2023earlyandextensive pages 6-8)
  • Microglia / macrophages (CD68+ infiltration early; strain-dependent activation patterns) (nishimura2023earlyandextensive pages 6-8, torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  • T cells (CD3+ infiltration early; CD4 and CD8 subsets present) (nishimura2023earlyandextensive pages 6-8)
  • Neurons (axons) (sources/targets of α-syn propagation; axonal Lewy neurites proposed precursors to GCIs in transfer model) (nuccio2023oligodendrocytespruneaxons pages 1-2)

3.4 Anatomical locations (UBERON style; commonly involved systems)

  • Striatonigral system (MSA-P predominant; putamen/substantia nigra involvement) (tanaka2025pathologicalandmolecular pages 1-2)
  • Olivopontocerebellar system (MSA-C predominant; cerebellar pathways; cerebellar afferent fiber demyelination staging) (tanaka2025pathologicalandmolecular pages 1-2, nishimura2023earlyandextensive pages 1-2)
  • Cerebellar white matter / cerebellar afferent fibers (site of staged demyelination and connexin pathology) (nishimura2023earlyandextensive pages 1-2)

4) GO-style biological processes and cellular components (for annotation)

4.1 Disrupted biological processes (representative GO terms; mapped to evidence)

  • Protein aggregation / amyloid fibril formation (α-syn misfolding and strain behavior; GCIs) (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  • Cell-to-cell propagation of misfolded proteins (“prion-like” transmission concept) (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2, nuccio2023oligodendrocytespruneaxons pages 1-2)
  • Autophagy and lysosome-mediated degradation (lysosomes/peroxisomes within GCIs; autophagy pathway implication) (boing2024distinctultrastructuralphenotypes pages 10-11)
  • Myelination and myelin maintenance (MAG/MOG changes; distal oligodendrogliopathy-type demyelination) (nishimura2023earlyandextensive pages 6-8)
  • Gap junction assembly/communication (Cx32 loss/redistribution; Cx43/Cx47 junction reduction) (nishimura2023earlyandextensive pages 6-8)
  • Immune activation / neuroinflammatory response (CD68+ microglia/macrophages; T cell infiltration early) (nishimura2023earlyandextensive pages 6-8)
  • Mitochondrial electron transport / ATP synthesis (COQ2/COQ7 expression associated with ATP reductions; CoQ10 deficiency) (hsiao2019reductionsincoq2 pages 2-4, mitsui2016plasmacoenzymeq10 pages 1-2)

4.2 Cellular components (representative GO CC terms; mapped to evidence)

  • Oligodendrocyte cytoplasm (GCIs) (nishimura2023earlyandextensive pages 1-2)
  • Lysosome / multivesicular body (abundant in GCIs by EM) (boing2024distinctultrastructuralphenotypes pages 10-11)
  • Peroxisome (identified vesicles co-localizing with α-syn pathology) (boing2024distinctultrastructuralphenotypes pages 10-11)
  • Myelin sheath / paranode (MAG/MOG changes; paranodal protein loss; connexin localization changes) (nishimura2023earlyandextensive pages 6-8)
  • Mitochondrion (bioenergetic/CoQ10 axis; ATP deficits) (hsiao2019reductionsincoq2 pages 2-4)

5) Disease progression model (sequence of events)

A synthesis consistent with the retrieved evidence is:

  1. Initiation/early molecular events: α-syn conformers emerge and/or are introduced/propagate; strain-like conformations may influence cell specificity and severity. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  2. Early oligodendroglial pathology: p-αSyn+ oligodendrocytes/GCIs appear early in staged lesions; in some models, neuronal pathology precedes oligodendroglial inclusions via transfer mechanisms. (nishimura2023earlyandextensive pages 6-8, nuccio2023oligodendrocytespruneaxons pages 1-2)
  3. Early myelin–axon unit failure: selective early MAG loss, early Cx32 loss/redistribution, and early paranodal marker reductions suggest impaired metabolic and electrical coupling and axonal support. (nishimura2023earlyandextensive pages 6-8)
  4. Inflammatory amplification: stage I lesions show pronounced microglia/macrophage infiltration and T-cell presence; strain-host interaction can modify immune response patterns. (nishimura2023earlyandextensive pages 6-8, torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  5. Proteostasis failure and organelle pathology: GCIs are enriched in lysosomes/multivesicular bodies and include peroxisomal components, implicating autophagy–lysosome axis in aggregate handling or dysfunction. (boing2024distinctultrastructuralphenotypes pages 10-11)
  6. Bioenergetic decline and oxidative stress: CoQ10/COQ2-linked mitochondrial compromise and ATP reductions in affected regions contribute to vulnerability and neurodegeneration. (hsiao2019reductionsincoq2 pages 2-4, mitsui2016plasmacoenzymeq10 pages 1-2)
  7. System degeneration and clinical convergence: initially predominant striatonigral vs olivopontocerebellar involvement can converge over time with widespread pathology. (tanaka2025pathologicalandmolecular pages 1-2)

6) Phenotypic manifestations linked to mechanisms (HP-style mapping)

  • Parkinsonism with poor levodopa response: linked to striatonigral degeneration and widespread network dysfunction in α-synucleinopathy with oligodendroglial dominance. (tanaka2025pathologicalandmolecular pages 1-2)
  • Cerebellar ataxia: linked to olivopontocerebellar atrophy and demyelination/oligodendroglial pathology in cerebellar pathways. (nishimura2023earlyandextensive pages 1-2, tanaka2025pathologicalandmolecular pages 1-2)
  • Autonomic dysfunction/failure: core clinical feature of MSA; reflects degeneration in autonomic pathways (clinical characterization in reviews and trial protocols). (tanaka2025pathologicalandmolecular pages 1-2, NCT05167721 chunk 1)
  • Cognitive impairment (subset): up to ~37% reported in clinicopathological studies summarized in early-stage review; may relate to broader inclusion distribution and neuronal dysfunction. (tanaka2025pathologicalandmolecular pages 1-2)

7) Recent developments and “latest research” emphasis (2023–2024)

7.1 2023–2024 advances in mechanistic understanding

  • Strain biology and host restriction (2023, Brain): Demonstrated that recombinant α-syn conformers differentially shape oligodendroglial inclusion properties, neurodegeneration, and immune activation, providing an experimental basis for heterogeneity in MSA progression. Publication: Feb 2023; URL: https://doi.org/10.1093/brain/awac061 (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  • Axon-to-oligodendrocyte transfer model (2023, Biomolecules): Proposed and experimentally supported a mechanism where oligodendrocytes acquire aggregated α-syn by pruning/engulfing diseased axonal segments, leading to GCI formation after an initial axonal/neuritic phase. Publication: Feb 2023; URL: https://doi.org/10.3390/biom13020269 (nuccio2023oligodendrocytespruneaxons pages 1-2)
  • Stage-resolved glial coupling and demyelination (2023, Brain Pathology): Introduced histopathological staging of cerebellar afferent demyelination and identified early Cx32 loss/redistribution and early immune infiltration. Publication: Nov 2023; URL: https://doi.org/10.1111/bpa.13131 (nishimura2023earlyandextensive pages 1-2, nishimura2023earlyandextensive pages 6-8)
  • Ultrastructural implicature of autophagy–lysosome and peroxisomes (2024, Brain): EM data show lysosomes and peroxisomes co-localize with α-syn pathology in GCIs (observed across >100 GCIs), strengthening the hypothesis that organelle trafficking/clearance pathways are centrally involved. Publication: May 2024; URL: https://doi.org/10.1093/brain/awae137 (boing2024distinctultrastructuralphenotypes pages 10-11)

7.2 Current expert synthesis (authoritative reviews)

A 2024 review emphasizes convergent “players” in MSA and PD—oxidative stress, iron-related pathology, mitochondrial/respiratory-chain dysfunction, proteasomal function loss, microglial activation and neuroinflammation—while acknowledging that precise causative mechanisms remain unclear and likely synergistic. Publication online: 25 May 2023; journal issue: May 2024; URL: https://doi.org/10.1007/s00702-023-02653-2 (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)

8) Current applications and real-world implementations

8.1 Biomarkers and imaging implementations

  • Biofluid α-synuclein oligomers (clinical research): Observational biomarker study assessing oligomeric α-synuclein levels in CSF and plasma (BIOAMS). ClinicalTrials.gov NCT01485549; first posted 2011-12-05; completion 2018-11-21. (NCT01485549 chunk 1)
  • Neuroinflammation imaging (TSPO PET) as pharmacodynamic biomarker: A completed pilot trial uses [18F]PBR06 TSPO PET to measure microglial activation and evaluate whether verdiperstat reduces TSPO signal in MSA. ClinicalTrials.gov NCT04616456; first posted 2020-11-05; completion 2022-01-30. (NCT04616456 chunk 1)
  • α-synuclein PET tracer development (real-world translational R&D): A completed observational study aims to develop an α-syn PET tracer (Morphomer-based; [18F]ACI-3847) to quantify in vivo α-syn load in MSA/PD/DLB and support future trials. ClinicalTrials.gov NCT05067192; first posted 2021-10-05; completion 2021-09-01. (NCT05067192 chunk 1)

8.2 Therapeutic strategies linked to mechanisms (clinical trials)

  • Anti-inflammatory/oxidative pathway targeting (MPO inhibitor): Verdiperstat (BHV-3241), an MPO inhibitor, tested in Phase 3 MSA trial with clinical endpoints (modified UMSARS over 48 weeks). ClinicalTrials.gov NCT03952806 (M-STAR); first posted 2019-05-16; results first posted 2023-09-29. (NCT03952806 chunk 1)
  • Regenerative/neurotrophic strategy: Intrathecal autologous mesenchymal stem cells (MSCs) are being evaluated for safety and exploratory efficacy with MRI/CSF biomarkers. ClinicalTrials.gov NCT02315027; first posted 2014-12-11; active-not-recruiting with estimated completion 2026-03. (NCT02315027 chunk 1)
  • Placebo-controlled MSC trial (adaptive design): Intrathecal adipose-derived autologous MSCs with UMSARS outcomes and NfL as biomarker. ClinicalTrials.gov NCT05167721; first posted 2021-12-22; active-not-recruiting with estimated completion 2026-12. (NCT05167721 chunk 1)

9) Recent statistics and data (from retrieved studies)

  • Neuropathology cohort and staging: 15 autopsied MSA cases staged into Stage I–III demyelination; early stage showed MAG loss, Cx32 loss/redistribution and higher immune infiltration. (nishimura2023earlyandextensive pages 1-2, nishimura2023earlyandextensive pages 6-8)
  • Ultrastructural sampling: Lysosomes/peroxisomes observed in >100 GCIs by EM, with “almost all” GCIs containing lysosomes and multivesicular bodies. (boing2024distinctultrastructuralphenotypes pages 10-11)
  • Genetic heritability: pooled heritability estimate ~2.09–6.65% reported in 2023 genetics review. (tseng2023thegeneticbasis pages 1-2)
  • Plasma CoQ10 (quantitative): 44 MSA vs 39 controls, 0.51 ± 0.22 μg/mL vs 0.72 ± 0.42 μg/mL, P=0.01. (mitsui2016plasmacoenzymeq10 pages 1-2)
  • Clinical trial sizes (implementation scale): Verdiperstat Phase 3 enrolled 421 participants (NCT03952806). (NCT03952806 chunk 1)

10) Evidence items (PMID/DOI-indexed)

PMIDs were not consistently present in the retrieved full-text excerpts; therefore, items are indexed by DOI/URL from the extracted evidence.

  1. Nishimura Y et al. Brain Pathology. 2023-11. “Early and extensive alterations of glial connexins…” DOI: 10.1111/bpa.13131. https://doi.org/10.1111/bpa.13131 (nishimura2023earlyandextensive pages 1-2, nishimura2023earlyandextensive pages 6-8)
  2. Böing C et al. Brain. 2024-05. “Distinct ultrastructural phenotypes…” DOI: 10.1093/brain/awae137. https://doi.org/10.1093/brain/awae137 (boing2024distinctultrastructuralphenotypes pages 10-11)
  3. Torre-Muruzabal T et al. Brain. 2023-02. “Host oligodendrogliopathy and α-synuclein strains…” DOI: 10.1093/brain/awac061. https://doi.org/10.1093/brain/awac061 (torremuruzabal2023hostoligodendrogliopathyand pages 1-3)
  4. De Nuccio F et al. Biomolecules. 2023-02. “Oligodendrocytes prune axons…” DOI: 10.3390/biom13020269. https://doi.org/10.3390/biom13020269 (nuccio2023oligodendrocytespruneaxons pages 1-2)
  5. Tseng FS et al. Journal of Translational Medicine. 2023-02. “The genetic basis of multiple system atrophy.” DOI: 10.1186/s12967-023-03905-1. https://doi.org/10.1186/s12967-023-03905-1 (tseng2023thegeneticbasis pages 1-2)
  6. Sian-Hulsmann J, Riederer P. Journal of Neural Transmission. Online 2023-05-25; issue 2024-05. DOI: 10.1007/s00702-023-02653-2. https://doi.org/10.1007/s00702-023-02653-2 (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2)
  7. Mitsui J et al. JAMA Neurology. 2016-08. “Plasma coenzyme Q10 levels…” DOI: 10.1001/jamaneurol.2016.1325. https://doi.org/10.1001/jamaneurol.2016.1325 (mitsui2016plasmacoenzymeq10 pages 1-2)
  8. Hsiao J-HT et al. Frontiers in Neuroscience. 2019-11. “Reductions in COQ2 expression relate to reduced ATP…” DOI: 10.3389/fnins.2019.01187. https://doi.org/10.3389/fnins.2019.01187 (hsiao2019reductionsincoq2 pages 2-4)

11) Notes on limitations of this report

  • A high-impact 2023 Nature Reviews Neuroscience review (“Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms”) and a 2024 Lancet Neurology review were identified by search but were unobtainable in the current tool context and therefore are not cited here.
  • PMIDs were not reliably present in the extracted evidence snippets; DOI/URL citations are used instead.

Appendix: Figure evidence (cropped)

  • Staged demyelination with MAG/MOG changes and p-αSyn+ oligodendrocytes (nishimura2023earlyandextensive media b572b16d)
  • Connexin redistribution (Cx32 vs Cx47) and Cx32 co-localization with p-αSyn+ GCIs (nishimura2023earlyandextensive media aa3bf217)

References

  1. (sianhulsmann2024the‘αsynucleinopathysyndicate’ pages 1-2): Jeswinder Sian-Hulsmann and Peter Riederer. The ‘α-synucleinopathy syndicate’: multiple system atrophy and parkinson’s disease. Journal of Neural Transmission, 131:585-595, May 2024. URL: https://doi.org/10.1007/s00702-023-02653-2, doi:10.1007/s00702-023-02653-2. This article has 13 citations and is from a peer-reviewed journal.

  2. (nishimura2023earlyandextensive pages 1-2): Yuji Nishimura, Katsuhisa Masaki, Dai Matsuse, Hiroo Yamaguchi, Tatsunori Tanaka, Eriko Matsuo, Shotaro Hayashida, Mitsuru Watanabe, Takuya Matsushita, Shoko Sadashima, Naokazu Sasagasako, Ryo Yamasaki, Noriko Isobe, Toru Iwaki, and Jun‐ichi Kira. Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy. Brain Pathology, Nov 2023. URL: https://doi.org/10.1111/bpa.13131, doi:10.1111/bpa.13131. This article has 8 citations and is from a domain leading peer-reviewed journal.

  3. (torremuruzabal2023hostoligodendrogliopathyand pages 1-3): Teresa Torre-Muruzabal, Anke Van der Perren, Audrey Coens, Géraldine Gelders, Anna Barber Janer, Sara Camacho-Garcia, Therése Klingstedt, Peter Nilsson, Nadia Stefanova, Ronald Melki, Veerle Baekelandt, and Wouter Peelaerts. Host oligodendrogliopathy and ɑ-synuclein strains dictate disease severity in multiple system atrophy. Brain : a journal of neurology, 146:237-251, Feb 2023. URL: https://doi.org/10.1093/brain/awac061, doi:10.1093/brain/awac061. This article has 20 citations.

  4. (boing2024distinctultrastructuralphenotypes pages 10-11): Carolin Böing, Marta Di Fabrizio, Domenic Burger, John G J M Bol, Evelien Huisman, Annemieke J M Rozemuller, Wilma D J van de Berg, Henning Stahlberg, and Amanda J Lewis. Distinct ultrastructural phenotypes of glial and neuronal alpha-synuclein inclusions in multiple system atrophy. Brain, 147:3727-3741, May 2024. URL: https://doi.org/10.1093/brain/awae137, doi:10.1093/brain/awae137. This article has 24 citations and is from a highest quality peer-reviewed journal.

  5. (compagnoni2019understandingthepathogenesis pages 4-6): Giacomo Monzio Compagnoni and Alessio Di Fonzo. Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives. Acta Neuropathologica Communications, Jul 2019. URL: https://doi.org/10.1186/s40478-019-0730-6, doi:10.1186/s40478-019-0730-6. This article has 111 citations and is from a peer-reviewed journal.

  6. (tanaka2025pathologicalandmolecular pages 1-2): Makoto T. Tanaka, Yasuo Miki, Tomoya Kon, Fumiaki Mori, and Koichi Wakabayashi. Pathological and molecular insights into the early stage of multiple system atrophy. Cells, 14:1966, Dec 2025. URL: https://doi.org/10.3390/cells14241966, doi:10.3390/cells14241966. This article has 4 citations.

  7. (federoff2015multiplesystematrophy pages 3-4): Monica Federoff, Lucia V. Schottlaender, Henry Houlden, and Andrew Singleton. Multiple system atrophy: the application of genetics in understanding etiology. Clinical Autonomic Research, 25:19-36, Feb 2015. URL: https://doi.org/10.1007/s10286-014-0267-5, doi:10.1007/s10286-014-0267-5. This article has 39 citations and is from a peer-reviewed journal.

  8. (hsiao2023roleofoligodendrocyte pages 2-4): Jen-Hsiang T. Hsiao, Onur Tanglay, Anne A. Li, Aysha Y. G. Strobbe, Woojin Scott Kim, Glenda M. Halliday, and YuHong Fu. Role of oligodendrocyte lineage cells in multiple system atrophy. Cells, 12:739, Feb 2023. URL: https://doi.org/10.3390/cells12050739, doi:10.3390/cells12050739. This article has 17 citations.

  9. (tanaka2025pathologicalandmolecular pages 2-5): Makoto T. Tanaka, Yasuo Miki, Tomoya Kon, Fumiaki Mori, and Koichi Wakabayashi. Pathological and molecular insights into the early stage of multiple system atrophy. Cells, 14:1966, Dec 2025. URL: https://doi.org/10.3390/cells14241966, doi:10.3390/cells14241966. This article has 4 citations.

  10. (nuccio2023oligodendrocytespruneaxons pages 1-2): Francesco De Nuccio, Marianna Kashyrina, Francesca Serinelli, Florent Laferrière, Dario Domenico Lofrumento, Francesca De Giorgi, and François Ichas. Oligodendrocytes prune axons containing α-synuclein aggregates in vivo: lewy neurites as precursors of glial cytoplasmic inclusions in multiple system atrophy? Biomolecules, 13:269, Feb 2023. URL: https://doi.org/10.3390/biom13020269, doi:10.3390/biom13020269. This article has 19 citations.

  11. (nishimura2023earlyandextensive pages 6-8): Yuji Nishimura, Katsuhisa Masaki, Dai Matsuse, Hiroo Yamaguchi, Tatsunori Tanaka, Eriko Matsuo, Shotaro Hayashida, Mitsuru Watanabe, Takuya Matsushita, Shoko Sadashima, Naokazu Sasagasako, Ryo Yamasaki, Noriko Isobe, Toru Iwaki, and Jun‐ichi Kira. Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy. Brain Pathology, Nov 2023. URL: https://doi.org/10.1111/bpa.13131, doi:10.1111/bpa.13131. This article has 8 citations and is from a domain leading peer-reviewed journal.

  12. (nishimura2023earlyandextensive media b572b16d): Yuji Nishimura, Katsuhisa Masaki, Dai Matsuse, Hiroo Yamaguchi, Tatsunori Tanaka, Eriko Matsuo, Shotaro Hayashida, Mitsuru Watanabe, Takuya Matsushita, Shoko Sadashima, Naokazu Sasagasako, Ryo Yamasaki, Noriko Isobe, Toru Iwaki, and Jun‐ichi Kira. Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy. Brain Pathology, Nov 2023. URL: https://doi.org/10.1111/bpa.13131, doi:10.1111/bpa.13131. This article has 8 citations and is from a domain leading peer-reviewed journal.

  13. (nishimura2023earlyandextensive media aa3bf217): Yuji Nishimura, Katsuhisa Masaki, Dai Matsuse, Hiroo Yamaguchi, Tatsunori Tanaka, Eriko Matsuo, Shotaro Hayashida, Mitsuru Watanabe, Takuya Matsushita, Shoko Sadashima, Naokazu Sasagasako, Ryo Yamasaki, Noriko Isobe, Toru Iwaki, and Jun‐ichi Kira. Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy. Brain Pathology, Nov 2023. URL: https://doi.org/10.1111/bpa.13131, doi:10.1111/bpa.13131. This article has 8 citations and is from a domain leading peer-reviewed journal.

  14. (mitsui2016plasmacoenzymeq10 pages 1-2): Jun Mitsui, Takashi Matsukawa, Tsutomu Yasuda, Hiroyuki Ishiura, and Shoji Tsuji. Plasma coenzyme q10 levels in patients with multiple system atrophy. JAMA neurology, 73 8:977-80, Aug 2016. URL: https://doi.org/10.1001/jamaneurol.2016.1325, doi:10.1001/jamaneurol.2016.1325. This article has 65 citations and is from a highest quality peer-reviewed journal.

  15. (hsiao2019reductionsincoq2 pages 2-4): Jen-Hsiang T. Hsiao, Sivaraman Purushothuman, Poul H. Jensen, Glenda M. Halliday, and Woojin Scott Kim. Reductions in coq2 expression relate to reduced atp levels in multiple system atrophy brain. Frontiers in Neuroscience, Nov 2019. URL: https://doi.org/10.3389/fnins.2019.01187, doi:10.3389/fnins.2019.01187. This article has 20 citations and is from a peer-reviewed journal.

  16. (tseng2023thegeneticbasis pages 1-2): Fan Shuen Tseng, Joel Qi Xuan Foo, Aaron Shengting Mai, and Eng-King Tan. The genetic basis of multiple system atrophy. Journal of Translational Medicine, Feb 2023. URL: https://doi.org/10.1186/s12967-023-03905-1, doi:10.1186/s12967-023-03905-1. This article has 25 citations and is from a peer-reviewed journal.

  17. (NCT04616456 chunk 1): Vikram Khurana, MD PhD. Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients. Brigham and Women's Hospital. 2020. ClinicalTrials.gov Identifier: NCT04616456

  18. (NCT03952806 chunk 1): Study of BHV-3241 in Participants With Multiple System Atrophy. Biohaven Pharmaceuticals, Inc.. 2019. ClinicalTrials.gov Identifier: NCT03952806

  19. (NCT05167721 chunk 1): Wolfgang Singer, MD. Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy. Mayo Clinic. 2021. ClinicalTrials.gov Identifier: NCT05167721

  20. (NCT01485549 chunk 1): Oligomeric Alpha-synuclein in Multiple System Atrophy. University Hospital, Bordeaux. 2012. ClinicalTrials.gov Identifier: NCT01485549

  21. (NCT05067192 chunk 1): Oskar Hansson. Optimization of Morphomer-based Alpha-synuclein PET Tracers. Skane University Hospital. 2021. ClinicalTrials.gov Identifier: NCT05067192

  22. (NCT02315027 chunk 1): Wolfgang Singer, MD. Mesenchymal Stem Cell Therapy in Multiple System Atrophy. Mayo Clinic. 2012. ClinicalTrials.gov Identifier: NCT02315027